CN115433283B - 用于癌症诊断的抗体 - Google Patents

用于癌症诊断的抗体 Download PDF

Info

Publication number
CN115433283B
CN115433283B CN202210691319.8A CN202210691319A CN115433283B CN 115433283 B CN115433283 B CN 115433283B CN 202210691319 A CN202210691319 A CN 202210691319A CN 115433283 B CN115433283 B CN 115433283B
Authority
CN
China
Prior art keywords
antibody
antigen
antibodies
cldn6
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210691319.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN115433283A (zh
Inventor
R·米特纳赫特-克劳斯
S·韦尔
K·瓦尔特
O·蒂雷西
U·沙欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Astellas Pharma Inc
Original Assignee
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers, Astellas Pharma Inc filed Critical Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Priority to CN202210691319.8A priority Critical patent/CN115433283B/zh
Publication of CN115433283A publication Critical patent/CN115433283A/zh
Application granted granted Critical
Publication of CN115433283B publication Critical patent/CN115433283B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202210691319.8A 2017-09-06 2018-09-05 用于癌症诊断的抗体 Active CN115433283B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210691319.8A CN115433283B (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/072386 WO2019048040A1 (en) 2017-09-06 2017-09-06 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EPPCT/EP2017/072386 2017-09-06
PCT/EP2018/073883 WO2019048489A1 (en) 2017-09-06 2018-09-05 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CN201880058261.5A CN111406070A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体
CN202210691319.8A CN115433283B (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880058261.5A Division CN111406070A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体

Publications (2)

Publication Number Publication Date
CN115433283A CN115433283A (zh) 2022-12-06
CN115433283B true CN115433283B (zh) 2024-05-24

Family

ID=59858709

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210691319.8A Active CN115433283B (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体
CN201880058261.5A Pending CN111406070A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体
CN202410880523.3A Pending CN118852435A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880058261.5A Pending CN111406070A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体
CN202410880523.3A Pending CN118852435A (zh) 2017-09-06 2018-09-05 用于癌症诊断的抗体

Country Status (15)

Country Link
US (3) US11279757B2 (cg-RX-API-DMAC7.html)
EP (2) EP3679069B1 (cg-RX-API-DMAC7.html)
JP (2) JP7277439B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230107371A (cg-RX-API-DMAC7.html)
CN (3) CN115433283B (cg-RX-API-DMAC7.html)
AU (2) AU2018327587B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003694B1 (cg-RX-API-DMAC7.html)
CA (1) CA3073157A1 (cg-RX-API-DMAC7.html)
ES (1) ES2998108T3 (cg-RX-API-DMAC7.html)
IL (2) IL293017A (cg-RX-API-DMAC7.html)
MX (2) MX393242B (cg-RX-API-DMAC7.html)
PL (1) PL3679069T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202000961SA (cg-RX-API-DMAC7.html)
WO (2) WO2019048040A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000851B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240084033A1 (en) * 2010-07-06 2024-03-14 Ganymed Pharmaceuticals Gmbh Cancer therapy using cldn6 target-directed antibodies in vivo

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
JP2025528148A (ja) * 2022-08-09 2025-08-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン-6抗体及びそのコンジュゲート及び使用
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1878793A (zh) * 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
CN101594883A (zh) * 2006-10-12 2009-12-02 株式会社未来创药研究所 使用抗ereg抗体的癌症的诊断和治疗
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
CN105407922A (zh) * 2013-07-31 2016-03-16 生物技术公司 涉及癌症干细胞的癌症的诊断与治疗
CN106519035A (zh) * 2010-07-06 2017-03-22 加尼梅德药物公司 体内利用cldn6靶标定向之抗体的癌症治疗
CN107011440A (zh) * 2011-05-13 2017-08-04 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US20100129929A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
EP3689911B1 (en) * 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1878793A (zh) * 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
CN101594883A (zh) * 2006-10-12 2009-12-02 株式会社未来创药研究所 使用抗ereg抗体的癌症的诊断和治疗
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
CN106519035A (zh) * 2010-07-06 2017-03-22 加尼梅德药物公司 体内利用cldn6靶标定向之抗体的癌症治疗
CN107011440A (zh) * 2011-05-13 2017-08-04 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
CN105407922A (zh) * 2013-07-31 2016-03-16 生物技术公司 涉及癌症干细胞的癌症的诊断与治疗

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AAC35165.1: anti-HIV-1 p24 antibody D2 kappa light chain, partial [Mus musculus];Genbank;《Genbank》;标题、PROTEIN、CDS、ORIGIN部分 *
AML31993.1: immunoglobulin heavy chain variable region, partial [Mus musculus];Genbank;《Genbank》;标题、PROTEIN、CDS、ORIGIN部分 *
Azadeh Arabzadeh、Tammy-Claire Troy、Kursad Turksen.Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorigenesis.《BMC Cancer》.2007,第7卷(第196篇),第1-8页. *
GenBank.AMN90531.1: immunoglobulin heavy chain variable region, partial [Mus musculus].《GenBank》.2016,标题、PROTEIN、CDS、ORIGIN部分. *
GenBank.CAA66140.1: nitrobenzyl esterolytic antibody kappa chain, partial [Mus musculus].《GenBank》.2016,标题、PROTEIN、CDS、ORIGIN部分. *
Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins;Sharon E Hopcraft、Matthew J Evans;《Hepatology》;第62卷(第04期);第1059-1069页 *
紧密连接蛋白CLDN6在卵巢癌、肝癌以及脑膜瘤组织中的表达及意义;刘亚芳等;《吉林大学学报(医学版)》;第36卷(第04期);第698-702页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240084033A1 (en) * 2010-07-06 2024-03-14 Ganymed Pharmaceuticals Gmbh Cancer therapy using cldn6 target-directed antibodies in vivo

Also Published As

Publication number Publication date
CA3073157A1 (en) 2019-03-14
AU2018327587B2 (en) 2023-05-04
MX393242B (es) 2025-03-24
BR112020003694A2 (pt) 2020-09-08
JP7277439B2 (ja) 2023-05-19
PL3679069T3 (pl) 2025-03-24
CN118852435A (zh) 2024-10-29
MX2020002243A (es) 2020-07-20
JP2023103315A (ja) 2023-07-26
SG11202000961SA (en) 2020-02-27
CN115433283A (zh) 2022-12-06
NZ761712A (en) 2025-08-29
AU2023208203A1 (en) 2023-08-17
EP4512830A2 (en) 2025-02-26
EP3679069C0 (en) 2024-11-20
JP2020532572A (ja) 2020-11-12
IL272487A (en) 2020-03-31
IL293017A (en) 2022-07-01
WO2019048040A1 (en) 2019-03-14
EP3679069A1 (en) 2020-07-15
ZA202000851B (en) 2021-08-25
KR20230107371A (ko) 2023-07-14
US20220162302A1 (en) 2022-05-26
BR112020003694B1 (pt) 2024-03-12
US11279757B2 (en) 2022-03-22
AU2018327587A1 (en) 2020-03-05
KR20200040784A (ko) 2020-04-20
EP4512830A3 (en) 2025-05-21
JP7882806B2 (ja) 2026-06-30
WO2019048489A1 (en) 2019-03-14
US11919951B2 (en) 2024-03-05
IL272487B (en) 2022-06-01
US20240209079A1 (en) 2024-06-27
MX2022007706A (es) 2022-07-19
KR102550489B1 (ko) 2023-07-03
EP3679069B1 (en) 2024-11-20
CN111406070A (zh) 2020-07-10
US20200199221A1 (en) 2020-06-25
ES2998108T3 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
JP2023109883A (ja) 癌診断に有用なクローディン18.2に対する抗体
US11919951B2 (en) Antibodies useful in cancer diagnosis
HK40085652A (en) Antibodies useful in cancer diagnosis
RU2815883C1 (ru) Антитела, пригодные в диагностике рака
HK40085652B (en) Antibodies useful in cancer diagnosis
HK40119074A (zh) 用於癌症诊断的抗体
HK40073623A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
HK40032868A (en) Antibodies useful in cancer diagnosis
NZ787569A (en) Antibodies useful in cancer diagnosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085652

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant